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Abstract
Background: The short-term effects of intravitreal ranibizumab (IVR) on diabetic macular edema (DME) remains
unclear. We assessed the short-term effects of IVR on DME.
Methods: Eighteen eyes of 14 patients with DME were enrolled in this prospective interventional case series. After
intravitreal ranibizumab was injected into treatment-naïve eyes with DME, we measured the foveal thickness (FT)
before and 2 h, 1 day, 1 week, and 1 month later and the best-corrected visual acuity (BCVA) at all times except 2 h
and compared the changes to baseline (ΔFT and ΔVA).
Results: The mean FT decreased significantly (p < 0.0001) from 452 ± 77 to 429 ± 65 microns after 2 h. The mean
logarithm of the minimum angle of resolution BCVA improved significantly (p = 0.032) after 1 month from 0.41 ± 0.24 to
0.32 ± 0.21 (20/51 to 20/42, Snellen equivalent). The ΔFT after 2 h was significantly (r = 0.53, p = 0.025) correlated with
the ΔFT after 1 month. The ΔVA after 1 day was significantly (r = 0.59, p = 0.01) correlated with the ΔVA after 1 month.
Conclusions: The structural effects of IVR for DME occurred within 2 h, whereas the functional effects occurred after
1 month. The short-term effects (within 1 day) of IVR may predict the therapeutic outcome 1 month after IVR in patients
with DME.
Trial registration: The trial registration number: UMIN000026118 (Feb/13/2017). Retrospectively registered.
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Background
Diabetic macular edema (DME) is the major cause of
visual loss in working age patients in developed countries
[1]. The efficacy of intravitreal ranibizumab (IVR) (Lucentis,
Novartis, Basel, Switzerland), a humanized affinity-matured
vascular endothelial growth factor (VEGF) antibody
fragment that specifically binds all isoforms of VEGF-A as a
therapy for DME is now well established. Multiple random-
ized, controlled clinical trials, including the DRCR.net
Protocol I [2, 3], RIDE and RISE [4, 5], READ 2 [6, 7],
RESOLVE [8], RESTORE [9, 10], and REVEAL [11], have
demonstrated visual improvement with IVR therapy. In
these clinical trials, the first evaluations of the therapeutic
effect on the foveal thickness (FT) and visual acuity (VA)
were performed 1 week [8] or 1 month [2–7, 9–11] after in-
jection of ranibizumab. To our knowledge, the short-term
effects, i.e., within a few hours, after IVR injection on DME
have not been evaluated. In the current study, we deter-
mined if the short-term effects (within 1 day) of IVR injec-
tion might predict the long-term (1 month) outcomes of
the FTand VA in patients with DME.
Methods
Subjects
The study adhered to the tenets of the Declaration of
Helsinki and followed the guidelines approved by the
ethics committee of our institution. All patients were na-
tive Japanese who provided informed consent before
participation in the study. Twenty-four consecutive eyes
of 20 patients with DME were enrolled and treated pros-
pectively with ranibizumab from April 2014 to May
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2015. The inclusion criteria were the presence of DME
before therapy (FT at baseline ≧ 300 microns) and no
history of ocular surgery (including laser) and/or other
treatment for macular edema within the previous
10 weeks. No patients were treated with a dexametha-
sone implant because the treatment has not yet been
approved in Japan. No patients had a history of intravit-
real anti-VEGF therapy. The exclusion criteria were the
logarithm of the minimum angle of resolution (logMAR)
VA below 0 (20/200, Snellen equivalent). The patients
underwent comprehensive ophthalmologic examinations
including measurement of the best-corrected VA (BCVA),
slit-lamp biomicroscopy with a noncontact fundus lens,
and spectral-domain optical coherence tomography
(SD-OCT) (RetinaScan RS-3000, Nidek, Gamagori,
Japan). The BCVA was measured using a standard
Japanese decimal VA chart at 5 m. The decimal values
were converted to logMAR units for statistical analyses.
To evaluate the FT, the macular map analysis protocol
of the RS-3000 SD-OCT was used. The FT was defined
as the average of all points in the inner circle (radius of
1 mm) at the center of the nine sectors defined by the
Early Treatment Diabetic Retinopathy Study grid [12].
IVR injection
IVR was administered in a sterile manner (0.5 mg/0.05 mL)
using a 30-gauge needle. Before injection, anterior chamber
paracentesis was performed using a 27-gauge needle to
prevent intraocular pressure increases. Topical antibiotics
were applied prophylactically for 1 week after the IVR
injection.
Time course of the evaluation of the therapeutic effect
of IVR
The FT was measured before the IVR injection (base-
line) and 2 h, 1 day, 1 week, and 1 month later. The
BCVA was measured at the same times except for 2 h
after the IVR injection. The changes in the FT (ΔFT)
(in microns) from baseline to each time point were cal-
culated and defined as the changes at 2 h, 1 day, 1 week,
and 1 month (ΔFT-2 h, −1d, −1w, and -1 m, respect-
ively). The changes in the logMAR VA (ΔVA) from
baseline also were calculated as ΔVA-1d, −1w, and
-1 m, respectively.
Data analysis
All values are expressed as the mean ± standard devi-
ation. We confirmed that the FTs and VAs at every
time point were normally distributed using the D’Agos-
tino-Pearson test. The overall differences in the FT at
baseline, 2 h, 1 day, 1 week, and 1 month after IVR
injection and in the logMAR VA at baseline, 1 day,
1 week, and 1 month after IVR injection were assessed
using repeated measures analysis of variance (ANOVA)
following Dunnett’s multiple comparisons test. To in-
vestigate if the early effectiveness of an IVR injection
predicts the late-phase outcome after an IVR injection,
the correlations between the ΔFT-2 h and the ΔFT-1 m
were evaluated using Pearson’s correlation model and
linear regression analysis. The correlations between the
ΔVA-1d and ΔVA-1 m also were evaluated using Pear-
son’s correlation model and linear regression analysis.
p < 0.05 was considered significant.
Results
One patient withdrew from the current study for per-
sonal reasons. Five eyes of five patients were excluded;
three patients underwent photocoagulation therapy
within 2 months and two patients had a VA lower than
20/200 Snellen equivalent. Eighteen eyes of 14 patients
were eligible in inclusion in this study. Fourteen eyes
had non-proliferative diabetic retinopathy, and four eyes
had proliferative diabetic retinopathy treated with pan-
retinal photocoagulation over 3 months before entry
into the current study. The average hemoglobin A1c
value was 6.8%. Table 1 shows the patient baseline
characteristics.
All patients had type 2 diabetes mellitus. No treatment
complications such as endophthalmitis or retinal detach-
ment developed during the study. Fig. 1 shows the time
course of the mean changes in the FT after IVR injec-
tion. The mean FT decreased significantly (p < 0.0001)
from the baseline value of 452 ± 77 microns to 429 ± 65
microns 2 h after the IVR injection. Significant (p =
0.002, p = 0.002, p = 0.0005) reductions also were seen to
417 ± 74, 387 ± 83, and 360 ± 84 microns on 1 day,
1 week, and 1 month, respectively.
Figure 2 shows the mean changes in the logMAR VA
after IVR injection. The mean logMAR VA improved
significantly (p = 0.032) from the baseline 0.41 ± 0.24
(20/51, Snellen equivalent) to 0.32 ± 0.21 (20/42, Snellen
Table 1 Baseline characteristics of patients with diabetic
macular edema
Age, years (mean ± SD) 62.9 ± 11.9
Men/women 8/6
Duration of diabetes (months, mean ± SD) 10.2 ± 7.6
DR scale (eyes) NPDR 14
PDR 4
Hemoglobin A1c (%) 6.8 ± 0.5
History of photocoagulation (eyes) 14 (57%)
History of cataract surgery (eyes) 6 (33%)
VA (logMAR, mean ± SD) 0.41 ± 0.24
Baseline FT (microns, mean ± SD) 452 ± 77
NPDR non-proliferative diabetic retinopathy, PDR proliferative diabetic retinopathy,
logMAR logarithm of the minimum angle of resolution, SD standard deviation,
VA visual acuity, FT foveal thickness
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equivalent) 1 month after IVR injection. The logMAR
VAs at 1 day (0.38 ± 0.20) and 1 week (0.35 ± 0.23) (20/
49 and 20/43, Snellen equivalent) after IVR injection did
not improve significantly (p = 0.62 and p = 0.12, respect-
ively) from baseline.
The ΔFT-2 h was correlated significantly (r = 0.53,
p = 0.025) with the ΔFT-1 m (Fig. 3). The ΔVA-1d was
correlated significantly (r = 0.59, p = 0.01) with the
ΔVA-1 m (Fig. 4). There was no significant (r = 0.34,
p = 0.17) correlation between the ΔFT-1 m and ΔVA-
1 m (Fig. 5).
There was no significant (p = 0.06) correlation between
the baseline BCVA and the ΔVA-1 m. The baseline
BCVA was significantly (p < 0.0001) correlated with the
BCVA at 1 month The baseline FT was significantly (p <
0.003) correlated with the FT at 1 month.
Discussion
The current study showed that the FT decreased sig-
nificantly 2 h after IVR injection in patients with DME.
Welch et al. [13] previously reported that the FT
decreased significantly 1 to 2 h after intravitreal injec-
tion of bevacizumab (IVB) (Avastin, Genentech Inc.,
South San Francisco, CA) in seven patients with DME
and two patients with exudative age-related macular
degeneration (AMD). Those investigators reported a
significant decrease in OCT thickness within 2 h after
injection. Although they used a different anti-VEGF
drug (bevacizumab) in patients with DME and AMD,
the results agree with the current findings.
Fig. 1 The mean changes in foveal thickness (FT) in 18 eyes at each
follow-up time point. The values are expressed as the mean ± standard
deviation. The FT is decreased significantly (*p < 0.01, **p < 0.001,
***p < 0.0001) from baseline
Fig. 2 The mean changes in the logarithm of minimum angle of
resolution (logMAR) best-corrected visual acuity (BCVA) at each
follow-up evaluation in 18 eyes. The values are expressed as the
mean ± standard deviation (Snellen equivalent). The BCVA is improved
significantly from baseline (*p < 0.05)
Fig. 3 The relationship between the changes in the foveal thickness
(FT) from baseline to 2 h (ΔFT-2 h) and the changes in FT from
baseline to 1 month (ΔFT-1 m) after intravitreal ranibizumab
injection. There is a significant (r = 0.53, p < 0.05) positive correlation
between them
Fig. 4 The relationship between changes in the logarithm of the
minimum angle of resolution (logMAR) best-corrected visual acuity
(BCVA) from baseline to 1 day (ΔVA-1d) and the changes in the
BCVA from baseline to 1 month (ΔVA-1 m) after injection. There is a
significant (r = 0.59, p < 0.05) positive correlation between them
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We observed a significant positive correlation between
the ΔFT-2 h and ΔFT-1 m (Fig. 3). The current results
suggested that we can predict the FT 1 month after an
IVR injection by measuring the FT as early as 2 h after
the IVR injection. Unfortunately, the long-term effect of
IVR remains unknown due to the current short follow-
up period. Therefore, we could not conclude definitively
if the short-term effects of an IVR injection is correlated
with the long-term effects more than 1 month after an
IVR injection administered to treat DME. Further study
with a longer follow-up period is warranted to examine
whether the long-term effects of an IVR injection can be
predictable based on the short-term effects.
Moreover, there was a significant correlation between
the ΔVA-1d and ΔVA-1 m (Fig. 4), suggesting that it is
possible to predict the BCVA 1 month after treatment
by measuring the BCVA 1 day after IVR injection. Ma
et al. reported that the FT 1 h after IVB injection signifi-
cantly decreased compared with baseline and that a
reduction in the FT 1 h after IVB was correlated signifi-
cantly with the reduction in the central macular thick-
ness 1 month after IVB injection in patients with both
DME and macular oedema after branch retinal vein
occlusion (BRVO) (total of 30 eyes). The authors specu-
lated that the FT 1 month after treatment might be pre-
dictable by measuring it a few hours after IVB injection
[14].
We found a significant correlation between the base-
line FT and the FT at 1 month. It was reported that the
baseline FT might predict the structural outcomes in re-
sponse to IVR therapy [15]. There also was a significant
correlation between the baseline BCVA and the BCVA
at 1 month. As previously reported, the baseline BCVA
might predict the functional outcome after IVR therapy
[9, 11]. Taken together, we speculated that measuring
the efficacy as early as 1 day after an IVR injection in
patients with DME might be predictive of the structural
and functional effects of the IVR injection in addition to
the prediction from the baseline FT and BCVA. In con-
trast, there was no significant (p = 0.06) correlation be-
tween the baseline BCVA and the ΔVA-1 m. However,
eyes with a low baseline VA tended to have a large in-
crease in the ΔVA-1 m in the current study as previously
reported [16].
Previous major clinical trials have reported that the
VA improvements from baseline tended to be associated
with reductions in the FT from baseline [2, 3, 9, 10, 17].
Indeed, there was a significant (r = 0.48, p < 0.05) correl-
ation between the ΔFT-1w and ΔVA-1w in the current
study. Another clinical study with a large number of pa-
tients is needed to confirm the correlation between the
improvements in BCVA and improvements in FT.
Pro re nata (PRN) regimens guided by VA have been
reported to be effective for treating DME [3, 10, 18, 19].
However, patients might be undertreated based on OCT
findings in treat-and-extend protocols [20]. In order to
choose adequate injection regimens, the ability to gauge
the required treatment intensity might be helpful. The
results of the current study indicated that the short-time
change could help with this and predict the long-term
response.
We recently determined the efficacy of IVR injections
in patients with macular edema due to BRVO [21]. In
BRVO, the FT decreased significantly at 2 h, 1 day,
1 week, and 1 month after IVR injections, the same as in
the current report. Although the baseline FT differed
(522 ± 131 μm vs 452 ± 77 μm, BRVO vs DME, p =
0.049), the ΔFTs were significantly higher in BRVO com-
pared with DME at 1 day, 1 week, and 1 month after
IVR injections if the ΔFT was divided by the baseline FT
(p < 0.001, by the two-way ANOVA and Sidak multiple
comparisons test) (data not shown). We speculated that
those differences in the efficacy of IVR injection between
DME and BRVO might have resulted from the differ-
ences in the mechanisms of the macular edema. Campo-
chiaro et al. reported that several cytokine levels in the
aqueous humor differed between DME and the macular
edema after BRVO [22]. Further clinical studies includ-
ing additional measurement of the intraocular cytokine
levels in eyes treated with IVR injections are needed to
clarify the differences between DME and macular edema
after BRVO. We also believe that measuring the short-
term effects of IVR injection is useful not only to predict
the efficacy but also to consider the difference in the
mechanisms of macular edema between DME and
BRVO.
The current study had some limitations. First, the
number of patients in this case series was too small to
perform a subgroup analysis. Another larger clinical
study is needed. Second, the current follow-up period
Fig. 5 The relationship between the changes in the foveal thickness
(FT) from baseline to 1 month (ΔFT-1 m) and the changes in the
logarithm of the minimum angle of resolution (logMAR) best-corrected
visual acuity (BCVA) from baseline to 1 month after injection. There is
no significant (r = 0.34, p = 0.17) correlation between them
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was short and another clinical study with a long follow-
up period is necessary to determine whether or not the
short-term effects of an IVR injection on the BCVA and
FT are correlated with the long-term effects of the IVR
injection on the BCVA. Third, the current study had no
control group. We could not exclude the influences of
the natural disease course or the effects of previous
treatments more than 10 weeks before IVR injection on
the current results. It was reported that retinal thickness
measurements vary over the course of a day [23]. In the
current study, we could not evaluate the effect of circa-
dian fluctuation and the reproducibility and variations in
the retinal thickness measurements in both healthy sub-
jects and patients. Another clinical study that includes a
control group and repeated measurements is needed.
Conclusion
In conclusion, the current findings suggested that the
structural effects of IVR injections might be detectable as
early as 1 day after treatment. We believe that evaluation
of the short-term effects of IVR injections can predict the
therapeutic outcome 1 month after IVR injection for
DME.
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